A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer : clinical results and biomarker analysis of GeparNuevo study

DSpace Repository

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer : clinical results and biomarker analysis of GeparNuevo study

Author: Loibl, S.; Untch, M.; Burchardi, N.; Huober, J.; Sinn, B., V; Blohmer, J-U; Grischke, E-M; Furlanetto, J.; Tesch, H.; Hanusch, C.; Engels, K.; Rezai, M.; Jackisch, C.; Schmitt, W. D.; von Minckwitz, G.; Thomalla, J.; Kuemmel, S.; Rautenberg, B.; Fasching, P. A.; Weber, K.; Rhiem, K.; Denkert, C.; Schneeweiss, A.
Tübinger Autor(en):
Grischke, Eva-Maria
Published in: Annals of Oncology (2019), Bd. 30, H. 8, S. 1279-1288
Verlagsangabe: Oxford Univ Press
Language: English
Full text: http://dx.doi.org/10.1093/annonc/mdz158
ISSN: 1569-8041
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)